PDS Biotechnology Corporation (PDSB) focuses on targeted cancer immunotherapies at the clinical stage. The $4.50 central target here is simply the arithmetic mean of two confirmed analyst estimates: B. Riley Securities issued a $4.00 Buy rating on October 29, 2026, while H.C. Wainwright reiterated its $5.00 Buy target on October 15, 2026. The range therefore sits between $4.00 and $5.00.
Both firms remain constructive even after the company’s restructuring. H.C. Wainwright has adjusted targets downward from earlier levels as high as $15 and $7, while B. Riley has moved its figure between $3 and $5 over the past year. In my view, this pattern underscores that the bullish case now hinges primarily on progress with the newer PDS0301 program.
In mid-November 2026 the shares traded near $1.00, inside a 52-week range of approximately $0.20 to $1.79. Closing the gap to $4.50 would call for an increase of about 350%, a sizable move with no assurance it will occur. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The path forward rests on clinical execution. Management has shared Phase 2 results for PDS0301, an IL-12 antibody-drug conjugate, in metastatic colorectal cancer with liver metastases. Responses appeared more durable in heavily pretreated patients, and a Phase 3 trial is slated to start around the first quarter of 2027. Strong Phase 3 outcomes could support a higher valuation, though delays or setbacks would weaken that outlook.
The stock hovers near the $1.00 level that has served as a focal point in recent trading. The 50-day moving average sits around $0.96 and the 200-day near $0.84, so the price remains above its longer-term trend despite recent softness. The 52-week high near $1.79 marks a key resistance area well below the $4.50 target, while the low near $0.20 represents the broader downside boundary. From what I see, a sustained move back above $1.00 could lift sentiment, yet meaningful progress toward the analyst target would likely need clinical catalysts rather than technical momentum alone.
Analyst targets generally reflect a roughly 12-month horizon, though timing is never guaranteed. Investors should track the next quarterly update expected in November 2026, along with any details on the PDS0301 Phase 3 design, enrollment progress, and further financing. Regulatory feedback, partnership news, insider or strategic buying, and any analyst target revisions also merit attention. Because the investment case is largely binary, shifts in the clinical timeline can drive sharp moves in either direction.
I occasionally turn to Tickeron’s AI Daily Buy/Sell Signals when reviewing names like this. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and data-driven analysis. For an event-driven micro-cap such as PDSB, it offers a practical way to monitor trends alongside fundamental work without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 74 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PDSB moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology